Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model

por Krishnatry, Anu Shilpa, Voelkner, Alexander, Dhar, Arindam, Prohn, Marita, Ferron‐Brady, Geraldine
Publicado 2021

Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors

por Krishnatry, Anu Shilpa, Hanze, Eva, Bergsma, Tim, Dhar, Arindam, Prohn, Marita, Ferron‐Brady, Geraldine
Publicado 2021

An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients

por Chau, Nicole G, Ma, Clement, Danga, Kristina, Al-Sayegh, Hasan, Nardi, Valentina, Barrette, Ryan, Lathan, Christopher S, DuBois, Steven G, Haddad, Robert I, Shapiro, Geoffrey I, Sallan, Stephen E, Dhar, Arindam, Nelson, Jeanenne J, French, Christopher A
Publicado 2019

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

por Piha-Paul, Sarina A, Hann, Christine L, French, Christopher A, Cousin, Sophie, Braña, Irene, Cassier, Phillippe A, Moreno, Victor, de Bono, Johann S, Harward, Sara Duckworth, Ferron-Brady, Geraldine, Barbash, Olena, Wyce, Anastasia, Wu, Yuehui, Horner, Thierry, Annan, Meg, Parr, Nigel J, Prinjha, Rabinder K, Carpenter, Christopher L, Hilton, John, Hong, David S, Haas, Naomi B, Markowski, Mark C, Dhar, Arindam, O’Dwyer, Peter J, Shapiro, Geoffrey I
Publicado 2019

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

por Dawson, Mark A., Borthakur, Gautam, Huntly, Brian J.P., Karadimitris, Anastasios, Alegre, Adrian, Chaidos, Aristeidis, Vogl, Dan T., Pollyea, Daniel A., Davies, Faith E., Morgan, Gareth J., Glass, Jacob L., Kamdar, Manali, Mateos, Maria-Victoria, Tovar, Natalia, Yeh, Paul, Delgado, Regina García, Basheer, Faisal, Marando, Ludovica, Gallipoli, Paolo, Wyce, Anastasia, Krishnatry, Anu Shilpa, Barbash, Olena, Bakirtzi, Evi, Ferron-Brady, Geraldine, Karpinich, Natalie O., McCabe, Michael T., Foley, Shawn W., Horner, Thierry, Dhar, Arindam, Kremer, Brandon E., Dickinson, Michael
Publicado 2023

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia

por Bell, Charles C., Fennell, Katie A., Chan, Yih-Chih, Rambow, Florian, Yeung, Miriam M., Vassiliadis, Dane, Lara, Luis, Yeh, Paul, Martelotto, Luciano G., Rogiers, Aljosja, Kremer, Brandon E., Barbash, Olena, Mohammad, Helai P., Johanson, Timothy M., Burr, Marian L., Dhar, Arindam, Karpinich, Natalie, Tian, Luyi, Tyler, Dean S., MacPherson, Laura, Shi, Junwei, Pinnawala, Nathan, Yew Fong, Chun, Papenfuss, Anthony T., Grimmond, Sean M., Dawson, Sarah-Jane, Allan, Rhys S., Kruger, Ryan G., Vakoc, Christopher R., Goode, David L., Naik, Shalin H., Gilan, Omer, Lam, Enid Y. N., Marine, Jean-Christophe, Prinjha, Rab K., Dawson, Mark A.
Publicado 2019